The biopharma company wanted to identify AL and ATTR amyloidosis patients with Cardiac amyloidosis early in the onset of the disease to shorten the disease diagnosis and prognosis time
Challenges
Early patient screening & identification is of paramount importance in ATTR patients as heart failure is almost inevitable in these cases. However, with traditional screening methods, timely diagnosis is difficult as the symptoms are rarely indicative of the disease and often lead to false positive screenings.
The Solution
- Deployed a framework and identified Phenotypic Cardiac Markers at different stages to screen and enroll patients
- Created a web and survey questionnaires based on insights generated from disease landscaping
- Interlinked page engagement data with our US + Bangalore call-center to enable outreach within 5-15 mins of pre-screener data-submission on study website
Outcomes
- Identified 3 biomarkers for optimal screening which are Primary Intrinsic CM, Renal Disease Induced Edema, and Cardiomegaly
- Screened 300 new patients every month
- Referred and Consented rate improved from 3% to 9%